molecule.one Raises $4.6M Seed Round for AI Drug Synthesis

Molecule.one Secures $4.6 Million to Advance Drug Synthesis Prediction

A Polish firm specializing in computational chemistry, Molecule.one, has successfully secured $4.6 million in funding. This investment will be utilized to further develop their efforts in translating theoretically promising drug molecules into tangible realities.

Addressing a Critical Bottleneck in Drug Discovery

Molecule.one initially presented their innovative approach at Disrupt SF 2019’s Startup Battlefield. They highlighted a significant challenge within the pharmaceutical industry: the frequent inability to synthesize molecules identified as potential treatments through theoretical research.

The company’s technology steps in when researchers require the creation of a novel compound for testing, yet lack a defined synthetic route. Given that these molecules represent uncharted territory in scientific exploration, established methods are often unavailable. Molecule.one generates a detailed workflow, beginning with readily available starting materials and providing sequential instructions based on established chemical methodologies to achieve the desired compound.

Leveraging Machine Learning for Synthesis Planning

The system employs machine learning algorithms and a comprehensive database of chemical reactions to devise these synthetic pathways. However, as Chief Scientific Officer Stanisław Jastrzębski explains, their approach is unconventional.

“Synthesis planning can be viewed as a strategic game,” Jastrzębski stated. “Each move involves breaking a chemical bond between atoms, rather than moving pieces on a board. The objective is to deconstruct a target molecule into commercially available precursors suitable for synthesis. We utilize algorithms akin to those employed by DeepMind in mastering games like Go and chess to identify the optimal synthesis pathway.”

Ensuring Reliability and Efficiency

Co-founders Piotr Byrski and Paweł Włodarczyk-Pruszyński emphasize the complexities of predicting organic reactions. They have dedicated substantial resources to enhance the system’s efficiency and ensure the validity of its predictions.

While the proposed pathways appear logical, rigorous testing is essential. Molecule.one conducts internal validation to demonstrate to clients that they deliver not merely promising concepts, but genuinely feasible solutions.

Platform Enhancements and Growing Customer Base

Since their initial appearance at Disrupt, Molecule.one has onboarded several clients with ongoing contracts and implemented numerous platform improvements. Włodarczyk-Pruszyński reports a significant increase in the system’s efficiency.

“Our platform has matured, now capable of planning synthesis for thousands of molecules per hour,” he noted. “This capability is particularly valuable when integrated with artificial intelligence systems used in drug discovery, which often generate a vast number of potential drug candidates. These advancements have fostered trust within the industry and facilitated collaborations with key stakeholders.”

Scaling to Meet Industry Demands

The challenge now lies in scaling operations to accommodate requests for synthesis pathways for hundreds of thousands of therapeutic molecules. For pharmaceutical companies, assessing the manufacturability of compounds early in the process is crucial, especially when considering the associated production costs.

Simulating the entire synthesis process is complex, making Molecule.one’s service invaluable. Clients can submit lists of compounds and receive detailed reports within days, enabling informed decision-making.

Supporting COVID-19 Research

While client successes remain confidential, the team confirms their involvement in supporting COVID-19 related therapeutic development.

“We provided free access to our platform for researchers engaged in COVID-19 drug discovery,” Byrski explained. “This led to a collaborative partnership with the LambdaZero project at MILA, advised by Prof. Yoshua Bengio.”

This collaboration also provided an opportunity to test and refine their new scaling methodologies, as evaluating numerous candidate molecules – both for efficacy and ease of manufacturing – was paramount.

Exploring Novel Chemical Space

“We are enthusiastic about this field as it allows exploration of previously uncharted regions of chemical space, offering significant potential for discovering novel drugs,” Byrski added.

Investment Details and Future Plans

The funding round was spearheaded by Atmos Ventures, with participation from AME Cloud Ventures, Cherubic Ventures, Firlej Kastory, Inventures, Luminous Ventures, Sunfish Partners, and individual investor Sebastian Guth, a Bayer executive.

Molecule.one intends to allocate the funds to team expansion and continued platform development. They also plan to establish new offices in the U.S. and Western Europe, complementing their existing base in Poland.